Jaguar Health Amends Supply Deal, Partner Covers Transition Costs
JAGX sits 23% above its 52-week low of $2.12.
Summary
Jaguar Health has amended its manufacturing and supply agreement with Woodward Specialty, clarifying inventory transfer and transition responsibilities. The amendment ensures business continuity through December 31, 2026, with Woodward covering certain related costs and liabilities. This operational stability is important for Jaguar Health, which recently reported a Q1 2026 financial turnaround after a period of significant distress.
At the time of this announcement, JAGX was trading at $2.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $2.12 to $115.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.